Read more
Nature is an attractive source of therapeutic compounds and with such chemical diversity found in millions of species of plants, over 60% of currently used anticancer agents are derived from natural sources. This volume summarizes advances in the experimental and clinical research of a selection of promising cancer inhibitors. It focuses on the latest scientific investigations of 240 Chinese herbs and discusses important aspects including the types of inhibitors in the herbs, level of potency, mechanisms, and the advances in modification and formulation. --
List of contents
Anticancer activities of exogenous pathogenic factor-eliminating herbs. Anticancer activities of antipyretic herbs. Anticancer activities of anti-rheumatics herbs. Anticancer activities of internal cold-dispelling herbs. Anticancer activities of vital energy-regulating herbs. Anticancer activities of blood-activating and stasis-resolving herbs. Anticancer activities of hemostatic herbs. Anticancer activities of expectorant, antitussive and anti-asthmatic herbs. Anticancer activities of tonic herbs. Anticancer potentials of purgative and diuretic herbs. Anticancer potentials of hard lump-resolving and swelling-reducing herbs. Anticancer agents from anti-spasmodic Chinese herbs. Anticancer of potentials of anthelmintic herbs. Anticancer activities of other plant herbs. Index for Latin Name of Chinese Herbs. Index for Chinese Names of Chinese Herbs. Index for English Name of Chinese Herbs. Index for Acronyms
About the author
Jun-Ping Xu earned a PhD in pharmaceutical sciences and medicinal chemistry at the Tokyo University of Pharmacy and Life Sciences in Japan in 1988. He has worked at the Shanghai Institute of Pharmaceutical Industry and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Dr. Xu currently works at the Cancer Research Institute and School of Molecular Sciences at Arizona State University, USA, as a research professor.
Summary
Cancer Inhibitors from Chinese Natural Medicines summarizes new advancements in the experimental and clinical research of a selection of promising cancer inhibitors.
